Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 14/20 | 0.65 |
| ▸ | AKR1C2 | P52895 | 14/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CDC42 | P60953 | 1/20 | 0.65 |
| ▸ | RAC1 | P63000 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11460825 | 1.00 | AKR1C3 (0.65) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL10041460 | 1.00 | AKR1C3 (0.65) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| Ammonia Solution, Strong SCHEMBL11722197 | 0.98 | AKR1C3 (0.63) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL11459076 | 0.95 | AKR1C3 (0.58) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL17369634 | 0.89 | AKR1C3 (0.53) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL15695568 | 0.89 | AKR1C3 (0.53) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL27634477 | 0.87 | CYP1A2 (0.50) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL11470486 | 0.85 | AKR1C3 (0.69) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL11721635 | 0.84 | CYP1A2 (0.46) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 | |
| SCHEMBL14983577 | 0.84 | CYP1A2 (0.46) | AKR1C3AKR1C2PTGS2PTGS1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023555-B2 | NSAIDs derivatives and uses thereof | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180162784-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2018-06-14 | — | — | US | disclosed |
| US-9850183-B2 | Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging | Reiley Pharmaceuticals, Inc. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850252-B2 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone, prodrugs, methods of making and use thereof | KEMPHARM, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170312270-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | ALTER DOMUS (US) LLC | 2017-11-02 | — | — | US | disclosed |
| US-20170196985-A1 | SULFUR(VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2017-07-13 | — | — | US | disclosed |
| US-9682076-B2 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof | KEMPHARM, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9512155-B2 | Chiral phosphines for palladium-catalyzed asymmetric α-arylation of ester enolates to produce tertiary stereocenters in high enantioselectivity | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-12-06 | — | — | US | disclosed |
| US-20160106712-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2016-04-21 | — | — | US | disclosed |
| US-20150374858-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | Reiley Pharmaceuticals, Inc. | 2015-12-31 | — | — | US | disclosed |
| US-20120115751-A1 | METHOD OF PREPARING AN ADDUCT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-05-10 | — | — | US | disclosed |
| US-8163806-B2 | Controlled release of biologically active compounds from multi-armed oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120095114-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120010284-A1 | CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2268617-B1 | PROCESS FOR THE RESOLUTION OF ISOQUINOLINE DERIVATIVES | RECORDATI CHEM PHARM (IT) | 2011-11-23 | — | — | EP | disclosed |
| US-8053591-B2 | Functionalized biodegradable triclosan monomers and oligomers for controlled release | BEZWADA BIOMEDICAL, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20030207919-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2003-11-06 | — | — | US | disclosed |
| US-6593347-B2 | Especially a nitrosated and/or nitrosylated arylpropionic acid, arylacetic acid, enolic anilide or an oxicam | NITROMED, INC. | 2003-07-15 | — | — | US | disclosed |
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NICOX S.A. (FR) | 2002-02-07 | — | — | US | disclosed |
| US-6297260-B1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED, INC. | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016322-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use | NOS2, NOS3, NOS1 | AKR1C3 464/4885AKR1C2 992/4885PTGS2 7/4885 |
| US-20170196985-A1 | SULFUR(VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF | CYP2F1, NAF1, CYP2S1 | AKR1C3 1453/4885AKR1C2 1861/4885PTGS2 4034/4885 |
| US-20170312270-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF OXYMORPHONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | OPRM1, OPRK1, OPRD1 | AKR1C3 382/4885AKR1C2 656/4885PTGS2 119/4885 |
| US-20160106712-A1 | FATTY ACID COX INHIBITOR DERIVATIVES AND THEIR USES | PTGES, PTGES2, ALOX5 | AKR1C3 626/4885AKR1C2 728/4885PTGS2 7/4885 |
| US-20180162784-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | AKR1C3 568/4885AKR1C2 1264/4885PTGS2 6/4885 |
| US-20120095114-A1 | FUNCTIONALIZED BIODEGRADABLE TRICLOSAN MONOMERS AND OLIGOMERS FOR CONTROLLED RELEASE | LTN1, PARN, TLR3 | AKR1C3 1554/4885AKR1C2 2335/4885PTGS2 2310/4885 |
| US-20150374858-A1 | CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING | PTGES3, PTGES, HPGDS | AKR1C3 568/4885AKR1C2 1264/4885PTGS2 6/4885 |
| US-10023555-B2 | NSAIDs derivatives and uses thereof | PTGES, PTGES3, PTGS1 | AKR1C3 716/4885AKR1C2 1089/4885PTGS2 6/4885 |
| US-20120010284-A1 | CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, AADAC, LGMN | AKR1C3 1454/4885AKR1C2 1709/4885PTGS2 3341/4885 |
| US-20030207919-A1 | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use | NOS2, NOS1, NOS3 | AKR1C3 290/4885AKR1C2 419/4885PTGS2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.